Gonthier Marie-Caroline, Gendron Nicolas, Eloy Philippine, Bourrienne Marie-Charlotte, Alhenc-Gelas Martine, Pouplard Claire, Tardy Bernard, Szymezak Jean, Burdet Charles, Gkalea Vasiliki, Faille Dorothée, Ajzenberg Nadine
Laboratory of Vascular Translational Science, Université de Paris, INSERM, et Laboratoire d'Hématologie, AH-HP, Bichat-Claude Bernard Hospital, Paris, France.
Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), Paris, France.
TH Open. 2021 Sep 24;5(4):e507-e512. doi: 10.1055/a-1653-5065. eCollection 2021 Oct.
Laboratory confirmation of heparin-induced thrombocytopenia (HIT) is of crucial importance and remains challenging and relies on platelet functional assays highlighting the presence of heparin-dependent platelet-activating antibodies in patient serum or plasma. Platelet functional assays using washed platelets include the C-serotonin release assay (SRA), usually described as the gold standard, and the heparin-induced platelet activation assay (HIPA). Since its first comparison with SRA there has been no additional published study regarding HIPA diagnostic performances compared with SRA. Aim of our retrospective study was to compare the concordance between HIPA and SRA in HIT suspected-patients with positive anti-PF4/heparin antibodies between October 2010 and October 2015. Fifty-five HIT-suspected patients who beneficiated from both HIPA and SRA were included. Positive and negative percent agreements were 83.8% (95% CI 68.0-93.8%) and 66.7% (95% CI 41.0-86.7%), respectively. Overall percent agreement was 78.2% (95% CI 65.0-92.2%). Agreement was higher in patients who underwent cardiopulmonary bypass with extracorporeal circulation circuit for cardiac surgery. We also confirm that the use of a minimum of 2 platelet donors to establish positive HIT diagnosis and 4 platelet donors to exclude HIT diagnosis allows obtaining a good agreement with SRA. Although HIPA and SRA were performed with different platelet donors and in different laboratories, HIPA had a good positive agreement with SRA for HIT diagnosis, showing that HIPA is a useful functional assay that does not require radioactivity and could be developed worldwide to improve HIT diagnosis.
肝素诱导的血小板减少症(HIT)的实验室确诊至关重要,但仍具有挑战性,且依赖于血小板功能检测,以突出患者血清或血浆中肝素依赖性血小板激活抗体的存在。使用洗涤血小板的血小板功能检测包括C - 5羟色胺释放试验(SRA),通常被视为金标准,以及肝素诱导的血小板激活试验(HIPA)。自首次与SRA比较以来,尚未有关于HIPA与SRA诊断性能比较的其他发表研究。我们回顾性研究的目的是比较2010年10月至2015年10月期间抗PF4/肝素抗体阳性的疑似HIT患者中HIPA与SRA之间的一致性。纳入了55例同时接受HIPA和SRA检测的疑似HIT患者。阳性和阴性百分比一致性分别为83.8%(95%可信区间68.0 - 93.8%)和66.7%(95%可信区间41.0 - 86.7%)。总体百分比一致性为78.2%(95%可信区间65.0 - 92.2%)。在接受心脏手术体外循环心肺转流的患者中一致性更高。我们还证实,使用至少2名血小板供体来确定HIT阳性诊断以及4名血小板供体来排除HIT诊断,与SRA具有良好的一致性。尽管HIPA和SRA是使用不同的血小板供体且在不同实验室进行的,但HIPA在HIT诊断方面与SRA具有良好的阳性一致性,表明HIPA是一种有用的功能检测方法,不需要放射性,并且可以在全球范围内开发以改善HIT诊断。